- Sequencing a patient's tumor before and after a clinical trial yielded information on why the tumor responded to and eventually resisted treatment, identifying mutations that may help guide the treatment of patients with cancers with similar mutations.
Tags: TranslationalResearch, HeadNeckCancers
- Carl Novina, MD, PhD, a researcher in the Department of Cancer Immunology and AIDS at Dana-Farber Cancer Institute, is one of 10 scientists chosen to receive a 2014 National Institutes of Health Pioneer Award, which funds bold and innovative research proposals to attack challenging biomedical problems.
- Dennie Jones, MD, has been named medical director of Dana-Farber Cancer Institute at St. Elizabeth's Medical Center.
- The Dana-Farber Marathon Challenge (DFMC) announced the team raised more than $8.2 million in its 25th running of the Boston Marathon® this year, the highest single-season fundraising total since the team's inception.
- Scientists at Dana-Farber Cancer Institute, the Massachusetts Institute of Technology, and other institutions have discovered a sign of the early development of pancreatic cancer – an upsurge in certain amino acids that occurs before the disease is diagnosed and symptoms appear. The research is being published online today by the journal Nature Medicine.
- Dana-Farber scientists and colleagues report on a compound that can stop the blood cancer multiple myeloma from spreading, leading to a new approach in addressing metastasis, one of the deadliest aspects of cancer.
Tags: BasicResearch, MultipleMyeloma
- Researchers from the Susan F. Smith Center for Women’s Cancers at Dana-Farber report that for some women with recurrent ovarian cancer, a new drug combination has been found to stall the progression of the disease.
Tags: OvarianCancer, GynecologicCancers
- The American Society of Clinical Oncology (ASCO) today issued a new clinical practice guideline on chemotherapy and targeted therapy for women with HER2-negative advanced breast cancer. The guideline provides detailed, evidenced-based information on the efficacy and side effects of various therapies.
- The Quality Oncology Practice Initiative (QOPI®) Certification Program, an affiliate of the American Society of Clinical Oncology (ASCO), has awarded Dana-Farber Cancer Institute a three-year certification for outpatient hematology-oncology practices that meet its highest standards for quality cancer care.
- The National Cancer Institute (NCI) has launched a new nationwide clinical trial to find out if two molecularly targeted drugs that have improved outcomes in advanced lung cancer can increase survival of patients with early-stage lung cancer that has been surgically removed.
Tags: LungCancer, TargetedTherapy
Showing 31-40 of 557 items